Not sure... I have always thought Painchek is trying to balance between a patient centric healthcare company vs a for profit hype micro-cap company. It has certainly leaned towards the former at the detriment of abysmal TSR for the past 2.5 years.
That said though.. I don't like the 4C update on assessments # vs the presentation.. the 4C commentary stipulated a much higher assessments done in the quarter vs what is shown on the investor presentation.. it's either misleading on intention or unprofessional in its proof reading.
Ann: Quarterly Investor Update Presentation, page-13
Add PCK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
0.007(21.2%) |
Mkt cap ! $65.43M | |||
| Open | High | Low | Value | Volume |
| 3.5¢ | 4.0¢ | 3.5¢ | $114.1K | 2.979M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 503170 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 5683729 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PCK (ASX) Chart |